All News
About Us
Our Services
CN PRnews Ratings
Partners
Press
Contact Us
ÖÐÎÄ°æ

 
 
Neuralstem Announces Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at the Upcoming American College of Neuropsychopharmacology Annual Meeting  
2017-11-17 09:59
    GERMANTOWN, Md., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that data from the Company’s Phase 2 study of NSI-189 in patients with major depressive disorder will be presented at the 56th American College of Neuropsychopharmacology (ACNP) Annual Meeting, which is being held in Palm Springs, California from December 3-7, 2017.

    Poster presentation details are as follows:

    Title: A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189 Phosphate, a Neurogenic Compound Among Out-Patients with Major Depressive Disorder

    Abstract Number: M79

    Session Title: Poster Session I

    Presenter: George Papakostas, M.D., Massachusetts General Hospital

    Date and Time: Monday, December 4, 2017, 5:30 PM – 7:30 PM PT

    About Neuralstem

    Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need. NSI-189 is a small molecule in clinical development for major depressive disorder (MDD) and in preclinical development for Angelman syndrome, irradiation-induced cognitive impairment, Type 1 and Type 2 diabetes, and stroke.

    NSI-566 is a stem cell therapy being tested for treatment of paralysis in stroke, chronic spinal cord injury (cSCI) and Amyotrophic Lateral Sclerosis (ALS). Neuralstem’s diversified portfolio of product candidates is based on its proprietary neural stem cell technology.

    Cautionary Statement Regarding Forward Looking Information

    This news release contains “forward-looking statements” made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including the Annual Report on Form 10-K for the year ended December 31, 2016, and Form 10-Q for the three and nine months ended September 30, 2017, filed with the Securities and Exchange Commission (SEC), and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.

    Contact:

    Kimberly Minarovich

    Argot Partners (Investor Relations)

    212-600-1902

    kimberly@argotpartners.com 

    

About GlobeNewswire

Source: GlobeNewswire
Web:

Disclaimer: Issuers of press releases and not China Business Press Release Newswire are solely responsible for the accuracy of the content. China Business Press Release Newswire is not responsible and will not be held liable for any third party content on PRnews.cn. Copyright 2004-2005, China Business Press Release Newswire. All Rights Reserved.
 
 Terms and Conditions of Use | Tixa.com | ChinaWI.com | NarrowAD.com

Copyright © 2005 Tixa technology CO., LTD. All rights reserved.